> ## Content Index > Fetch the complete content index at: https://www.foodconsumer.org/llms.txt > Use this file to discover other available public pages before exploring further. # FDA Updates for Health Professionals - URL: https://www.foodconsumer.org/fda_updates_for_health_professionals_0115150111/ - Published: 2015-01-15T14:11:00.000Z - Updated: 2026-09-22T16:19:12.000Z - Description: An FDA roundup for health professionals: a Drug Info Rounds video on disposing of unused medicines, a Medscape interview on new labeling for pregnant and breastfeeding women, and open comment requests on risk disclosure in direct-to-consumer TV drug ads. - Author: Food Consumer - Tags: Government, Health News, #vivvo-import ![HP NL masthead ](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/eed7527adf7f027547ea1c8362c246279168afac.jpg) **January 14, 2015** ![ocha](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/1e1264e4505937850cb7ac35af6c2552fe8135d9.png) # ANNOUNCEMENTS | ![Microphone with FDA Logo](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/aa35d7d082b5937bfe461668852917ebf20bfcb3.jpg) FDA Drug Info Rounds Video: Disposal of Unused Medicines What do patients do with medications that have not been used or are out of date? FDA Drug Info Rounds pharmacists discuss medication disposal options and some special disposal instructions for your patients to consider when throwing out expired, unwanted, or unused medicines. [More information](http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm429508.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ### Medscape Expert Interview Series: FDA Updates Labels for Pregnant and Breastfeeding Women In this interview with Medscape, FDA experts Melissa S. Tassinari, PhD, and Jeanine Best, MSN, RN, PNP, from the Center for Drug Evaluation and Research, Division of Pediatric and Maternal Health, explain how the new labeling will help providers make more informed decisions. [More information](http://www.fda.gov/ForHealthProfessionals/ucm274874.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ### From our Perspective: Patients Deserve Quality Medications Lawrence X. Yu, Ph.D., Acting Director of FDA’s Center for Drug Evaluation and Research’s Office of Pharmaceutical Science, discusses the important roles of FDA and drug companies in ensuring quality drug products. [More information](http://www.fda.gov/Drugs/NewsEvents/ucm428298.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ![divider](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/517c6b8897909338c1814dc416a2d32f131f66a3.png) # OPPORTUNITIES FOR COMMENT / GUIDANCES | ![Comments image](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/c8a9ffc156e15c2f2b6fb519bb9b6a252690b9ce.jpg) Comment Request: Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements There is concern that as currently implemented in DTC ads, the major statement is often too long, which may result in reduced consumer comprehension, minimization of important risk information and, potentially, therapeutic non-compliance due to fear of side effects. At the same time, there is concern that DTC TV ads do not include adequate risk information or leave out important information. [More information](https://www.federalregister.gov/articles/2015/01/13/2015-00269/agency-information-collection-activities-submission-for-office-of-management-and-budget-review?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ### Comment Request: Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic The guidance includes recommendations for planning, notification, and documentation for firms that report postmarketing adverse events. [More information](https://www.federalregister.gov/articles/2015/01/06/2014-30907/agency-information-collection-activities-submission-for-office-of-management-and-budget-review?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery)[ ](https://www.federalregister.gov/articles/2015/01/06/2014-30907/agency-information-collection-activities-submission-for-office-of-management-and-budget-review?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ### Comment Request: Evaluation of the Food and Drug Administration's Multicultural Youth Tobacco Prevention Campaigns The 2009 Family Smoking Prevention and Tobacco Control Act amended the Federal Food, Drug, and Cosmetic Act to grant FDA authority to regulate the manufacture, marketing, and distribution of tobacco products to protect public health and to reduce tobacco use by minors. [More information](https://www.federalregister.gov/articles/2015/01/05/2014-30808/agency-information-collection-activities-proposed-collection-comment-request-evaluation-of-the-food?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ![divider](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/517c6b8897909338c1814dc416a2d32f131f66a3.png) # PRODUCT APPROVALS & CLEARANCES | ![FDA Approved](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/5843bc738ca49b80d5625b9f26c4fa752d9206af.jpg) FDA approves anti-clotting drug Savaysa FDA approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation that is not caused by a heart valve problem. Savaysa also has been approved to treat deep vein thrombosis and pulmonary embolism in patients who have already been treated with an anti-clotting drug administered by injection or infusion, for five to ten days. [More information](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429523.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ### FDA grants first CLIA waiver for nucleic acid-based flu diagnostic test FDA granted the first waiver to allow a nucleic acid-based test, the Alere i Influenza A & B test, to be used in a greater variety of health care settings. The test was previously only available for use in certain laboratories. [More information](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429127.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | ![Drugs@FDA](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/4c745dfa81bc9ea669768203efc2a64b42f5a24b.gif) For more information on drug approvals or to view prescribing information and patient information, please visit [Drugs at FDA](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) or[DailyMed](http://dailymed.nlm.nih.gov/dailymed/about.cfm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ![divider](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/517c6b8897909338c1814dc416a2d32f131f66a3.png) # PRODUCT SAFETY | ![MedWatch Image](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/5051b0767ba5864734aa1de671e17316e0ff302c.jpg) To receive MedWatch Safety Alerts by email [subscribe here](http://www.fda.gov/Safety/MedWatch/ucm228488.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery). For more important safety information on human drug and devices or to report a problem to FDA, please visit [MedWatch.](http://www.fda.gov/Safety/MedWatch/default.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | ![Pregnant Woman](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/e44acdc8da3f33ec2907925adc217efe98492f51.jpg) Prescription and Over-the-Counter (OTC) Pain Medicines: Drug Safety Communication - FDA Review of Possible Risks of Pain Medicine Use During Pregnancy FDA is aware of and understands the concerns arising from recent reports questioning the safety of prescription and over-the-counter pain medicines when used during pregnancy. As a result, FDA evaluated research studies published in the medical literature and determined they are too limited to make any recommendations based on these studies at this time. [More information](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm429604.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ### Virazole (Ribavirin Powder for Solution) by Valeant Pharmaceutical North America: Recall- Microbial Contamination Valeant Pharmaceuticals North America LLC (VPNA) is issued a voluntarily recall of one lot of Virazole (ribavirin powder for solution), 100 mL, 6g Vial, 4-pack to the user level. [More information](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm428700.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ### Comunicaciones de la FDA sobre la seguridad de los medicamentos en español Descargo de responsabilidad: La FDA reconoce la necesidad de proporcionar información sobre seguridad importante en idiomas distintos al inglés. Hacemos lo mejor posible para proporcionar versiones en español precisas y oportunas de nuestras Comunicaciones de Seguridad de Medicamentos. Sin embargo, en caso que existiera discrepancias entre las versiones en ingles y en español, la información contenida en la versión en inglés es la que se considera como versión oficial. Si tiene alguna pregunta, por favor contáctese con Division of Drug Information en[druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov). [Comunicaciones de la FDA](http://www.fda.gov/Drugs/DrugSafety/ucm263010.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ![divider](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/35ba118f3ddac80c50317ab70ba914c0d34fa686.png) # UPCOMING MEETINGS FDA advisory committee meetings are free and open to the public. No prior registration is required to attend. Interested persons may present data, information, or views, orally at the meeting, or in writing, on issues pending before the committee. Other types of meetings listed may require prior registration and fees. Click on "more information" for details about each meeting. Please visit FDA’s Advisory Committee webpage for [more information](http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery). Please visit Meetings, Conferences, & Workshops for [more information](http://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/default.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) on other agency meetings. ![January](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/c48094a04c6bcc92f5ac78a9860b4fdcd33e1376.png) ### Anti-Infective Drugs Advisory Committee Meeting (Jan 22) The committee will discuss new drug applications (NDAs) 207-500 and 207-501, isavuconazonium sulfate capsules and isavuconazonium sulfate for injection, sponsored by Astellas Pharma Global Development, Inc., respectively for the proposed indications of treatment of invasive aspergillosis and mucormycosis. [More information](http://www.fda.gov/AdvisoryCommittees/Calendar/ucm424436.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ![feb](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/026b00037b220ce15e4c850b722989c8d3ff6285.png) ### FDA-AAPS-ACCP-ASCPT Co-sponsored Workshop - Evaluating and Modernizing our Approaches for Food-Effect Assessment (Feb 2-4) The goals of this public workshop are to facilitate discussion on current scientific approaches on assessing the effect of food on the pharmacokinetics and pharmacodynamics of drugs, and to initiate constructive discussion and information sharing among relevant stakeholders on the influence of food-effects on the pharmacokinetic properties of therapeutics in order to optimize dose and dosing regimens. [More information](http://www.fda.gov/Drugs/NewsEvents/ucm429663.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ### Orthopaedic and Rehabilitation Devices Panel (Feb 20) The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the Superion InterSpinous Spacer device sponsored by Vertiflex Incorporated.[More information ](http://www.fda.gov/AdvisoryCommittees/Calendar/ucm426248.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ### Public Workshop - Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests (Feb 20) The purpose of this workshop is to discuss and receive feedback from the community on FDA’s regulatory approach to diagnostic tests for human genetics or genomics using Next Generation Sequencing (NGS) technology. [More information](http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm427296.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ### General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee (Feb 27) The committee will discuss, make recommendations and vote on information regarding the premarket approval application (PMA) panel-track supplement to expand the indication for use for the Radiesse Injectable Implant (Radiesse) device to include subdermal implantation for hand augmentation to correct volume deficit in the hands. [More information](http://www.fda.gov/AdvisoryCommittees/Calendar/ucm427763.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ![divider](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/517c6b8897909338c1814dc416a2d32f131f66a3.png) # RESOURCES | ![MWLearn](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/7876883d5839144371fd2b900b3b31721a74ef56.jpg) MedWatchLearn - Practice Reporting to FDA! This web-based learning tool teaches students, health professionals, and consumers how to complete the forms necessary to report problems to FDA.[More information ](http://www.accessdata.fda.gov/scripts/MedWatchLearn/?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ### FDA Expert Commentary and Interview Series on Medscape As part of the continuing collaboration between FDA and Medscape, a series of interviews and commentaries are available to communicate important safety information to clinicians. Featuring FDA experts, these original commentaries cover a wide range of topics related to FDA's multi-faceted mission of protecting and promoting the public health by ensuring the safety and quality of medical products such as drugs, foods, and medical devices [More information ](http://www.fda.gov/ForHealthProfessionals/ucm274874.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | ![EKG](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/a23ea94fcaee399d0889c707918329af19c0f11b.png) | | Cardiovascular and Endocrine Liaison Program The Cardiovascular and Endocrine Liaison Program serves as a liaison between the FDA and the cardiovascular and endocrine health professional and patient communities. Discover how you or your organization can collaborate with FDA. [More information](http://www.fda.gov/ForHealthProfessionals/LiaisonActivities/ucm402222.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | ------------------------------------------------------------------------------------------------------------------------------------------------- | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | | FDA Basics Each month, different Centers and Offices at FDA will host an online session where the public can ask questions to senior FDA officials about a specific topic or just listen in to learn more about FDA. [More information](http://www.fda.gov/AboutFDA/Transparency/Basics/default.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) FDA Voice FDA voice is the official blog from FDA's senior leadership and staff.[More information](https://blogs.fda.gov/?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) | | ![Computer Resource](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/2feead53cb994f8847ddb7e0eb0b461fda3f2cd3.jpg) | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | --------------------------------------------------------------------------------------------------------------------------------------------------------------- | ### Medical Product Safety Network (Medsun) Medsun improves FDA's understanding of problems with the use of medical devices so that the FDA, healthcare facilities, clinicians, and manufacturers can better address safety concerns. The Medsun newsletter provides monthly updates about timely medical device issues that may impact patient safety. [More information](http://www.fda.gov/MedicalDevices/Safety/MedSunMedicalProductSafetyNetwork/default.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) [](https://blogs.fda.gov/?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) ![OOCHA](https://storage.ghost.io/c/f5/c2/f5c28c07-f2c7-440d-8161-125a09d9bc91/content/images/2026/08/1fa946ebfe9dc6ce0553fa95305c3edd405d2e21.png)